CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
Globe Newswire•28/08/2026•10:31 ET
0
Whiz Insights
Get started
Create a free account to read the full story.